UK – NICE ‘OK’ for Lynparza

The National Institute for Health and Care Excellence (NICE) has recommended MSD and AstraZeneca’s (AZ) Lynparza (olaparib) tablets, for adults who have relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer with a BRCA1 or BRCA2 mutation.

The decision was based on a clinical trial in which the drug stalled growth of the cancer for around 13.6 months compared to placebo.

The news means that the first-in-class PARP inhibitor is now recommended for routine use in the NHS for people who have had three or more courses of platinum-based chemotherapy, with an estimated 100 people eligible for the treatment through routine commissioning.

However, the organisation has confirmed that for patients who have had two courses of platinum-based chemotherapy, the treatment does not meet NICE’s end-of-life criteria…